Amesika N Nyaku1, Lu Zheng2, Roy M Gulick3, Maxine Olefsky2, Baiba Berzins4, Carole L Wallis5, Catherine Godfrey6, Paul E Sax7, Edward P Acosta8, David W Haas9,10, Kimberly Y Smith11, Beverly E Sha12, Cornelius N Van Dam13, Babafemi O Taiwo4. 1. Rutgers University, Newark, NJ, USA. 2. Harvard T. H. Chan School of Public Health, Boston, MA, USA. 3. Weill Cornell Medical College, New York, NY, USA. 4. Northwestern University, Chicago, IL, USA. 5. BARC-SA and Lancet Laboratories, Johannesburg, South Africa. 6. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA. 7. Brigham and Women's Hospital, Boston, MA, USA. 8. University of Alabama, Birmingham, AL, USA. 9. Vanderbilt University, Nashville, TN, USA. 10. Meharry Medical College, Nashville, TN, USA. 11. ViiV Healthcare, Research Triangle Park, NC, USA. 12. Rush University Medical Center, Chicago, IL, USA. 13. Regional Center for Infectious Diseases, Cone Health, Greensboro, NC, USA.
Abstract
BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES: The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and compare the efficacy in participants with baseline HIV-1 RNA ≤100 000 copies/mL versus >100 000 copies/mL. METHODS: Virological success was defined as HIV-1 RNA <50 copies/mL by FDA Snapshot criteria. Definition of virological failure included confirmed HIV-1 RNA >200 copies/mL at week 24 or later. The proportion of participants with virological success was estimated using two-sided exact Clopper-Pearson 95% CI. Comparison between screening HIV-1 RNA (≤100 000 versus >100 000 copies/mL) strata was carried out by Fisher's exact test. The study was registered with ClinicalTrials.gov, number NCT02582684. RESULTS: A total of 120 enrolled eligible participants were included in the analysis. At week 48, 102 of the 120 participants (85%; 95% CI 77%-91%) had virological success. Virological success was similar between screening HIV-1 RNA groups. Six (5%) participants had virological non-success and one additional participant experienced virological failure while on study but off study treatment. No new drug resistance mutations were observed. Six (5%) participants had study-related grade 3 or higher adverse events and none discontinued study treatment. CONCLUSIONS: These results add to the evidence that dolutegravir plus lamivudine is a safe and effective option for initial ART in individuals with HIV-1 RNA <500 000 copies/mL.
BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES: The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and compare the efficacy in participants with baseline HIV-1 RNA ≤100 000 copies/mL versus >100 000 copies/mL. METHODS: Virological success was defined as HIV-1 RNA <50 copies/mL by FDA Snapshot criteria. Definition of virological failure included confirmed HIV-1 RNA >200 copies/mL at week 24 or later. The proportion of participants with virological success was estimated using two-sided exact Clopper-Pearson 95% CI. Comparison between screening HIV-1 RNA (≤100 000 versus >100 000 copies/mL) strata was carried out by Fisher's exact test. The study was registered with ClinicalTrials.gov, number NCT02582684. RESULTS: A total of 120 enrolled eligible participants were included in the analysis. At week 48, 102 of the 120 participants (85%; 95% CI 77%-91%) had virological success. Virological success was similar between screening HIV-1 RNA groups. Six (5%) participants had virological non-success and one additional participant experienced virological failure while on study but off study treatment. No new drug resistance mutations were observed. Six (5%) participants had study-related grade 3 or higher adverse events and none discontinued study treatment. CONCLUSIONS: These results add to the evidence that dolutegravir plus lamivudine is a safe and effective option for initial ART in individuals with HIV-1 RNA <500 000 copies/mL.
Authors: Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng Journal: Lancet Date: 2012-06-30 Impact factor: 79.321
Authors: Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith Journal: Lancet Date: 2018-11-09 Impact factor: 79.321
Authors: Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Edwin DeJesus; Jürgen K Rockstroh; Keith Henry; Jean-Michel Molina; Joseph Gathe; Srinivasan Ramanathan; Xuelian Wei; Kitty Yale; Javier Szwarcberg; Kirsten White; Andrew K Cheng; Brian P Kearney Journal: Lancet Date: 2012-06-30 Impact factor: 79.321
Authors: Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar Journal: Lancet Date: 2009-08-03 Impact factor: 79.321
Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2014 Jun-Jul
Authors: Pedro Cahn; María José Rolón; María Inés Figueroa; Ana Gun; Patricia Patterson; Omar Sued Journal: J Int AIDS Soc Date: 2017-05-09 Impact factor: 5.396
Authors: Joel Gallant; Adriano Lazzarin; Anthony Mills; Chloe Orkin; Daniel Podzamczer; Pablo Tebas; Pierre-Marie Girard; Indira Brar; Eric S Daar; David Wohl; Jürgen Rockstroh; Xuelian Wei; Joseph Custodio; Kirsten White; Hal Martin; Andrew Cheng; Erin Quirk Journal: Lancet Date: 2017-08-31 Impact factor: 79.321
Authors: Mohamed N'dongo Sangaré; Jean-Guy Baril; Alexandra de Pokomandy; Steve Ferreira Guerra; Mabel Carabali; Claudie Laprise; Réjean Thomas; Marina Klein; Cécile Tremblay; Michel Roger; Costa Pexos; Zoë R Greenwald; Nima Machouf; Madeleine Durand; Isabelle Hardy; Mamadou Dakouo; Andrea Trevisan; Louise Laporte; Mireille E Schnitzer; Helen Trottier Journal: Open Forum Infect Dis Date: 2020-09-04 Impact factor: 3.835
Authors: Lauren Greenberg; Lene Ryom; Bastian Neesgaard; Gilles Wandeler; Therese Staub; Martin Gisinger; Michael Skoll; Huldrych F Günthard; Alexandra Scherrer; Cristina Mussini; Colette Smith; Margaret Johnson; Stéphane De Wit; Coca Necsoi; Christian Pradier; Ferdinand Wit; Clara Lehmann; Antonella d'Arminio Monforte; Jose M Miró; Antonella Castagna; Vincenzo Spagnuolo; Anders Sönnerborg; Matthew Law; Jolie Hutchinson; Nikoloz Chkhartishvili; Natalia Bolokadze; Jan-Christian Wasmuth; Christoph Stephan; Vani Vannappagari; Felipe Rogatto; Josep M Llibre; Claudine Duvivier; Jennifer Hoy; Mark Bloch; Heiner C Bucher; Alexandra Calmy; Alain Volny Anne; Annegret Pelchen-Matthews; Jens D Lundgren; Lars Peters; Loveleen Bansi-Matharu; Amanda Mocroft Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer Journal: J Antimicrob Chemother Date: 2019-11-01 Impact factor: 5.790